No Data
A subsidiary has been "blacklisted" by Shenzhen for one year. Jointown Pharmaceutical Group claims to be "in the process of defending". The industry believes that the intensity of procurement supervision is continuously increasing.
Recently, Jointown Pharmaceutical Group's subsidiary, Jointown Medical Device, was fined and banned from participating in Shenzhen procurement for one year due to providing false information in a tender at a hospital in Shenzhen. Jointown Pharmaceutical Group responded to a reporter from Caijing.com.cn, stating that this incident is a pending matter, and they have organized appeal materials and are currently undergoing administrative reconsideration. This year, several listed companies have been fined for violations in the bidding and procurement process, leading industry insiders to suggest that companies should pay more attention to compliance with details during the bidding process.
shanghai microport endovascular medtech(group)co.,ltd. net profit increased by more than 44% in the first half of the year. Can going overseas alleviate the impact of Castor's price reduction?
1. Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. accelerates its 'going global' strategy, with overseas revenue increasing by 67.04% in the first half of the year, accounting for 8.84% of the total revenue; 2. The reporter from the 'Star Market Daily' asked employees of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. whether they would correspondingly adjust the prices facing dealers in response to the significant price reduction of Castor brackets' terminal. The other party refused to disclose more information, citing 'inconvenience to reply.'
Continued high investment in R&D and advancing market expansion, Autobio Diagnostics' first-half revenue and net profit both doubled, according to the announcement.
①Autobio Diagnostics achieved growth in both H1 revenue and net profit, with the proportion of R&D expenses in total revenue continuously increasing. ②The revenue proportion of the company's reagent business did not increase as expected. ③The company plans to add actual production support for specific subfields in the content of the 'Expansion Project of In Vitro Diagnostic Product Capacity' project.
Factory production is 0.05 million, and agents sell 0.12 million? The latest response from the National Medical Insurance Bureau to Shanghai Microport Endovascular Medtech(Group)Co.,Ltd.'s four questions has arrived.
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. received an inquiry letter from the National Medical Insurance Bureau due to the suspected overpricing of Castor stents. Company employees revealed that internal meetings are being held to address this issue. In order to cope with competition pressure in the domestic market, including pressure from early response to centralized procurement, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. is accelerating its layout in overseas markets.
Breaking news! The CEO of this joint-stock bank suddenly resigned, and the director will take over his duties. | Summary of after-hours announcements.
Yes Optoelectronics: Currently, the company's products have not been applied in the field of AI glasses, and there are no signed agreements or orders.
Baike Biotech's net income increased by almost 24%. How long can the first-mover advantage for its shingles vaccine last?
①Since 2023, Baike Biotech's performance in the first half of the year has continued to grow positively, but compared to the same period last year and the first quarter of this year, both revenue and net income growth rates have significantly declined; ②Since 2024, at least five companies have submitted new drug applications for herpes zoster vaccines, Baike Biotech reminds that it may gradually lose its first-mover advantage for herpes zoster vaccines in the future.